| Dr James G Mackenzie, DO | |
|
4440 W 95th St, Oak Lawn, IL 60453-2600 | |
| (708) 684-7999 | |
| Not Available |
| Full Name | Dr James G Mackenzie |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | 4440 W 95th St, Oak Lawn, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811068554 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0804X | Psychiatry & Neurology - Child & Adolescent Psychiatry | 036111117 (Illinois) | Primary |
| Entity Name | Advocate Health And Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700824455 PECOS PAC ID: 7810800935 Enrollment ID: O20031106000064 |
News Archive
These days most children born with congenital heart disease live well into adulthood, thanks to innovative surgical, interventional and medical treatments.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
The Senate Finance Committee will delay its vote on health care reform — and, likely the bill's move to the Senate floor — as members await cost estimates by the Congressional Budget Office.
High epidermal growth factor receptor expression was a good predictor of which lung cancer patients would survive longer when cetuximab was added to first-line chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James G Mackenzie, DO 29373 Network Pl, Chicago, IL 60673-1293 Ph: () - | Dr James G Mackenzie, DO 4440 W 95th St, Oak Lawn, IL 60453-2600 Ph: (708) 684-7999 |
News Archive
These days most children born with congenital heart disease live well into adulthood, thanks to innovative surgical, interventional and medical treatments.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
The Senate Finance Committee will delay its vote on health care reform — and, likely the bill's move to the Senate floor — as members await cost estimates by the Congressional Budget Office.
High epidermal growth factor receptor expression was a good predictor of which lung cancer patients would survive longer when cetuximab was added to first-line chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.
› Verified 2 days ago
Dr. Paul A Dobransky, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4440 W 95th St, Oak Lawn, IL 60453 Phone: 708-684-7482 | |
Dr. Utpal H Dhruve, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4440 W 95th St, Oak Lawn, IL 60453 Phone: 708-684-7482 | |
Leah M Ustas, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4440 W 95th St, Oak Lawn, IL 60453 Phone: 708-684-7482 | |
Phillip Bryce Jones, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4440 W 95th St, Oak Lawn, IL 60453 Phone: 405-990-5460 | |
Jessica M Nicholson, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4400 W 95th St Ste 404, Oak Lawn, IL 60453 Phone: 708-684-3980 Fax: 708-684-3980 | |
Aliya Hafeez, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4440 W 95th St, Oak Lawn, IL 60453 Phone: 708-684-7482 | |
Miss Rochelle Tayel Sweis, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4440 W 95th St, Oak Lawn, IL 60453 Phone: 708-684-8000 |